Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 5/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29633361 | 1.00 | ALDH1A1 (0.69) | ALDH1A1CYP1A2CYP3A4ALKCYP2A6 | |
| Hydrochloric Acid SCHEMBL1493357 | 0.98 | ALDH1A1 (0.67) | ALDH1A1CYP1A2CYP3A4ALKCYP2A6 | |
| SCHEMBL11245286 | 0.85 | CYP1A2 (0.63) | ALDH1A1CYP1A2CYP3A4ALKCYP2A6 | |
| SCHEMBL3078162 | 0.80 | CYP3A4 (0.89) | ALDH1A1CYP1A2CYP3A4ALKCYP2A6 | |
| SCHEMBL168659 | 0.79 | POLB (0.61) | CYP1A2AURKBPIM1HPGDSMKNK1 | |
| SCHEMBL12056298 | 0.79 | ALDH1A1 (0.69) | ALDH1A1CYP1A2CYP3A4ALKCYP2A6 | |
| SCHEMBL1436058 | 0.79 | ALK (1.00) | ALDH1A1CYP1A2CYP3A4ALKCYP2A6 | |
| SCHEMBL3608558 | 0.78 | CYP2A6 (1.00) | ALDH1A1CYP1A2CYP3A4ALKCYP2A6 | |
| SCHEMBL17980230 | 0.77 | AURKA (0.42) | ALDH1A1CYP1A2CYP3A4ALKCYP2A6 | |
| SCHEMBL238785 | 0.77 | MKNK2 (0.47) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570659-B2 | Bicyclic heteroaryl compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-08 | — | — | US | disclosed |
| EP-4013758-B1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025202955-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS | PI INDUSTRIES LTD. (IN) | 2025-10-02 | — | — | WO | disclosed |
| US-12275739-B2 | Inhibitors of menin-MLL interaction | BIOMEA FUSION, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-2024038132-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
| US-11845753-B2 | Inhibitors of menin-mll interaction | BIOMEA FUSION, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220380372-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-12-01 | — | — | US | disclosed |
| EP-4013758-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-101679287-A | nicotinic acetylcholine receptor modulators | SIENA BIOTECH SPA | 2010-03-24 | — | — | CN | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
| CN-101374810-A | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof | SIENA BIOTECH SPA (IT) | 2009-02-25 | — | — | CN | disclosed |
| EP-1991528-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007098826-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275739-B2 | Inhibitors of menin-MLL interaction | MLLT1, MEN1, MLLT3 | ALDH1A1 4585/4885CYP1A2 4624/4885CYP3A4 4509/4885 |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | ALDH1A1 1444/4885CYP1A2 543/4885CYP3A4 285/4885 |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | ALDH1A1 4453/4885CYP1A2 4565/4885CYP3A4 4582/4885 |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | ALDH1A1 1232/4885CYP1A2 1261/4885CYP3A4 2371/4885 |
| US-20220380372-A1 | BICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | ALDH1A1 3655/4885CYP1A2 3728/4885CYP3A4 1382/4885 |
| US-20240140953-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | ALDH1A1 4585/4885CYP1A2 4624/4885CYP3A4 4509/4885 |
| US-12570659-B2 | Bicyclic heteroaryl compounds useful as IRAK4 inhibitors | IRAK4, IRAK1, IRAK3 | ALDH1A1 3865/4885CYP1A2 3638/4885CYP3A4 2262/4885 |
| US-11845753-B2 | Inhibitors of menin-mll interaction | MLLT1, MEN1, MLLT3 | ALDH1A1 4585/4885CYP1A2 4624/4885CYP3A4 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.